Ohara Hirotaka, Nakazawa Takahiro, Sano Hitoshi, Ando Tomoaki, Okamoto Tetsu, Takada Hiroki, Hayashi Kazuki, Kitajima Yasuhiro, Nakao Haruhisa, Joh Takashi
Department of Internal Medicine and Bioregulation, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Pancreas. 2005 Oct;31(3):232-7. doi: 10.1097/01.mpa.0000175178.85786.1d.
Autoimmune pancreatitis (AIP) is often associated with systemic extrapancreatic lesions. We studied 31 cases of AIP to clarify the diversity of associated systemic extrapancreatic lesions and the differences between AIP with and without systemic extrapancreatic lesions.
The clinical features and courses were compared by age, sex, and blood chemistry between those with and without systemic extrapancreatic lesions. In addition, we reviewed the available literature on systemic extrapancreatic lesions with AIP.
Seven of the 31 cases of AIP had associated systemic extrapancreatic lesions, which were diagnosed simultaneously with AIP; however, 1 case presenting with various extrapancreatic lesions was diagnosed independently of the AIP lesion. Patients with systemic extrapancreatic lesions needed maintenance steroid therapy for AIP in 4 cases and systemic extrapancreatic lesions in 2 cases; the ratio of cases requiring maintenance steroid therapy was significantly higher among those with systemic extrapancreatic lesions (6/8) than those without (7/23). There were no significant differences between groups with regard to age, sex, extent of narrowing of the main pancreatic duct, and enlargement of the pancreas. gamma-globulin, IgG, and IgG4 levels were significantly higher in patients with AIP with systemic extrapancreatic lesions than those without. The systemic extrapancreatic lesions associated with AIP found in the literature were Sjögren syndrome, ulcerative colitis, retroperitoneal fibrosis, sialadenitis, thyroiditis, and idiopathic thrombocytopenic purpura.
The results of this study suggest that, when encountering a case of AIP with elevated levels of gamma-globulins, IgG, and IgG4, an effort should be made to detect other systemic extrapancreatic abnormalities and initiate steroid administration.
自身免疫性胰腺炎(AIP)常与全身性胰腺外病变相关。我们研究了31例AIP患者,以阐明相关全身性胰腺外病变的多样性以及有和无全身性胰腺外病变的AIP之间的差异。
比较有和无全身性胰腺外病变患者的年龄、性别和血液生化指标的临床特征及病程。此外,我们回顾了关于AIP全身性胰腺外病变的现有文献。
31例AIP患者中有7例伴有全身性胰腺外病变,这些病变与AIP同时被诊断;然而,1例出现各种胰腺外病变的患者是独立于AIP病变被诊断的。有全身性胰腺外病变的患者中,4例因AIP需要维持性类固醇治疗,2例因全身性胰腺外病变需要维持性类固醇治疗;有全身性胰腺外病变的患者中需要维持性类固醇治疗的比例(6/8)显著高于无全身性胰腺外病变的患者(7/23)。两组在年龄、性别、主胰管狭窄程度和胰腺肿大方面无显著差异。有全身性胰腺外病变的AIP患者的γ-球蛋白、IgG和IgG4水平显著高于无全身性胰腺外病变的患者。文献中发现的与AIP相关的全身性胰腺外病变有干燥综合征、溃疡性结肠炎、腹膜后纤维化、涎腺炎、甲状腺炎和特发性血小板减少性紫癜。
本研究结果表明,当遇到γ-球蛋白、IgG和IgG4水平升高的AIP病例时,应努力检测其他全身性胰腺外异常并开始给予类固醇治疗。